80 related articles for article (PubMed ID: 23494564)
1. Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells.
Deng L; Zhang E; Chen C
Arch Pharm Res; 2013 May; 36(5):619-25. PubMed ID: 23494564
[TBL] [Abstract][Full Text] [Related]
2. A glycosylated nitric oxide donor, beta-Gal-NONOate, and its site-specific antitumor activity.
Chen C; Shi Y; Li S; Qi Q; Gu L; Song J; Wang PG
Arch Pharm (Weinheim); 2006 Jul; 339(7):366-71. PubMed ID: 16783837
[TBL] [Abstract][Full Text] [Related]
3. β-galactosyl-pyrrolidinyl diazeniumdiolate: an efficient tool to investigate nitric oxide functions on promoting cell death.
Chen C; Zhang E
Appl Microbiol Biotechnol; 2013 Aug; 97(16):7377-85. PubMed ID: 23801048
[TBL] [Abstract][Full Text] [Related]
4. Delivery of nitric oxide released from beta-Gal-NONOate activation by beta-galactosidase and its activity against Escherichia coli.
Chen C; Shi YQ; Song J; Qi QS; Gu L; Wang PG
Biol Pharm Bull; 2006 Jun; 29(6):1239-41. PubMed ID: 16755024
[TBL] [Abstract][Full Text] [Related]
5. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
7. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
8. Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins.
Safdar S; Taite LJ
Int J Pharm; 2012 Jan; 422(1-2):264-70. PubMed ID: 22101282
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of 5-fluorouracil cytotoxicity by cisplatin in brain tumour cell lines.
Mineura K; Kowada M
Cell Biol Int; 1996 May; 20(5):355-7. PubMed ID: 8688852
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
11. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
12. A polyethylenimine-based diazeniumdiolate nitric oxide donor accelerates wound healing.
Zhang Y; Tang K; Chen B; Zhou S; Li N; Liu C; Yang J; Lin R; Zhang T; He W
Biomater Sci; 2019 Mar; 7(4):1607-1616. PubMed ID: 30702089
[TBL] [Abstract][Full Text] [Related]
13. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
[TBL] [Abstract][Full Text] [Related]
15. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
16. Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor.
Nakagawa M; Yamaguchi T; Fukawa H; Ogata J; Komiyama S; Akiyama S; Kuwano M
Jpn J Cancer Res; 1985 Apr; 76(4):315-20. PubMed ID: 2408954
[TBL] [Abstract][Full Text] [Related]
17. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
Adhim Z; Lin X; Huang W; Morishita N; Nakamura T; Yasui H; Otsuki N; Shigemura K; Fujisawa M; Nibu K; Shirakawa T
Cancer Gene Ther; 2012 Feb; 19(2):144-52. PubMed ID: 22116375
[TBL] [Abstract][Full Text] [Related]
18. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells.
Wang X; Wong SC; Pan J; Tsao SW; Fung KH; Kwong DL; Sham JS; Nicholls JM
Cancer Res; 1998 Nov; 58(22):5019-22. PubMed ID: 9823301
[TBL] [Abstract][Full Text] [Related]
19. Probenecid is a chemosensitizer in cancer cell lines.
Campos-Arroyo D; Martínez-Lazcano JC; Melendez-Zajgla J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):495-504. PubMed ID: 21861129
[TBL] [Abstract][Full Text] [Related]
20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
